See inside every stock. Pro
S&P 5007,377▲ 0.31%Nasdaq24,579▲ 1.09%Dow Jones51,286▼ 0.46%Nasdaq 10026,990▲ 1.35%VIX25.64▼ 9.01%US Dollar102.28▲ 0.72%Gold spot4,066▼ 0.49%WTI90.83▲ 0.34%

AGFiQ U.S. Market Neutral Anti-Beta (BTAL)

Equity ETF · US-listed · NYSE ARCA · 405 holdings
$13.25 ▼ -0.36 (2.65%)
At close · USD · Volume 1,893,700
52-week range
$10.86 – $16.14
Day's range
$13.24 – $13.45
1-year total return
−9.7%

BTAL price chart

Daily, split-corrected, distributions markedEnd-of-day prices

BTAL fund facts

FundAGFiQ U.S. Market Neutral Anti-Beta Fund
TickerBTAL · NYSE ARCA
Issuer (by our rules)–
Category (by our rules)Equity
Expense ratio1.40%
Holdings405
Net assets (fund, SEC)$283M
Yield (last 12 months)2.70%
DistributionsAnnual
52-week range$10.86 – $16.14
Average volume (3 months)903,581
First price in our data13 Sep 2011
Issuer and category are assigned by StocksXray rules from the fund name. Expense ratio and net assets come from SEC filings; where a fund does not file them (for example grantor trusts) the field stays empty.

Returns and risk

1 month
+11.3%
3 months
+8.9%
6 months
+11.9%
Year to date
−7.9%
1 year
−9.7%
3 years a year
−10.7%
5 years a year
−1.5%
10 years a year
−3.3%
Volatility (1 year)
24.4%
Largest drop, last year
−29.2%
Largest drop in our data
−52.7%
Total return includes distributions, from end-of-day prices adjusted for splits and distributions, to 6 Nov 2026. Periods of 3 years and longer are annualised and shown only when the fund's history is long enough. Volatility is the standard deviation of daily returns over the last year, annualised. Past performance does not guarantee future results.

Cost: expense ratio

1.40% a year

On $10,000 invested that is about $140 a year in fund costs, taken out of the fund's assets. The prospectus shows 1.65% before fee waivers.

Source: the fund's prospectus, as filed with the SEC on 27 Oct 2025 (risk/return summary data). Brokerage commissions and the bid-ask spread are separate costs.

Income: distributions

Paid, last 12 months
0.36 USD
Yield on today's price
2.70%
Frequency
Annual
Latest ex-date
30 Dec 2025
Full BTAL dividend history →
Cash paid per current share (restated for share splits), before tax, from our market-data provider.

BTAL top holdings

#HoldingWeight
1 Okta, Inc. 0.63%
2 Molina Healthcare, Inc. 0.53%
3 Rivian Automotive, Inc. 0.51%
4 Cardinal Health, Inc. CAH 0.51%
5 AbbVie, Inc. ABBV 0.50%
6 Simpson Manufacturing Co., Inc. 0.49%
7 Cloudflare, Inc. 0.48%
8 DaVita, Inc. DVA 0.48%
9 Lucid Group, Inc. 0.48%
10 Teledyne Technologies, Inc. TDY 0.48%
The top 10 make up 5.1% of the fund, out of 405 holdings.
Positions as of 30 Jun 2026, from the fund's Form N-PORT filed with the SEC. Public N-PORT holdings are quarter-end positions published about 60 days later, so they can be months old and the fund may have changed since.

BTAL: frequently asked questions

What is BTAL?

BTAL is the AGFiQ U.S. Market Neutral Anti-Beta ETF, listed on NYSE ARCA. By our rules it is classed as "Equity". Its latest SEC filing lists 405 holdings.

What is the expense ratio of BTAL?

BTAL charges 1.40% a year after fee waivers (gross 1.65%), according to its prospectus filed with the SEC on 27 Oct 2025. On $10,000 that is about $140 a year in fund costs.

Does BTAL pay dividends?

Yes. BTAL paid 0.36 per share over the last 12 months, annual, a trailing yield of 2.70% on today's price. The latest ex-dividend date was 30 Dec 2025.

What does BTAL hold?

The largest holdings in the latest SEC filing are Okta, Inc. (0.6%), Molina Healthcare, Inc. (0.5%), Rivian Automotive, Inc. (0.5%). The top 10 together make up 5.1% of the fund.

How has BTAL performed?

Total return including distributions to 6 Nov 2026: 1 year −9.7%, 3 years −10.7% a year, 5 years −1.5% a year. Past performance does not guarantee future results.

Where the numbers come from

Prices and distributions end-of-day data from our market-data provider; returns are our own calculations from it.
Expense ratio and holdings SEC filings (prospectus risk/return data and Form N-PORT).
Category, issuer and leverage assigned by StocksXray rules from the fund name.
X-Ray look-through our scores applied to the SEC holdings.
Read the methodology →

StocksXray is for education only and is not financial advice or a recommendation to buy or sell anything. Past performance does not guarantee future results; funds can lose value.